A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival

Jianjun Yu, Jindan Yu, Kevin E. Cordero, Michael D. Johnson, Debashis Ghosh, James M. Rae, Arul M. Chinnaiyan, Marc E Lippman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Estrogen signaling plays an essential role in breast cancer progression, and estrogen receptor (ER) status has long been a marker of hormone responsiveness. However, ER status alone has been an incomplete predictor of endocrine therapy, as some ER+ tumors, nevertheless, have poor prognosis. Here we sought to use expression profiling of ER+ breast cancer cells to screen for a robust estrogen-regulated gene signature that may serve as a better indicator of cancer outcome. We identified 532 estrogen-induced genes and further developed a 73-gene signature that best separated a training set of 286 primary breast carcinomas into prognostic subtypes by stepwise cross-validation. Notably, this signature predicts clinical outcome in over 10 patient cohorts as well as their respective ER+ subcohorts. Further, this signature separates patients who have received endocrine therapy into two prognostic subgroups, suggesting its specificity as a measure of estrogen signaling, and thus hormone sensitivity. The 73-gene signature also provides additional predictive value for patient survival, independent of other clinical parameters, and outperforms other previously reported molecular outcome signatures. Taken together, these data demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance.

Original languageEnglish
Pages (from-to)79-88
Number of pages10
JournalNeoplasia
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Dermatoglyphics
Estrogen Receptors
Estrogens
Breast Neoplasms
Survival
Genes
Hormones
Neoplasms
Cell Culture Techniques
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Yu, J., Yu, J., Cordero, K. E., Johnson, M. D., Ghosh, D., Rae, J. M., ... Lippman, M. E. (2008). A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia, 10(1), 79-88. https://doi.org/10.1593/neo.07859

A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. / Yu, Jianjun; Yu, Jindan; Cordero, Kevin E.; Johnson, Michael D.; Ghosh, Debashis; Rae, James M.; Chinnaiyan, Arul M.; Lippman, Marc E.

In: Neoplasia, Vol. 10, No. 1, 01.01.2008, p. 79-88.

Research output: Contribution to journalArticle

Yu, J, Yu, J, Cordero, KE, Johnson, MD, Ghosh, D, Rae, JM, Chinnaiyan, AM & Lippman, ME 2008, 'A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival', Neoplasia, vol. 10, no. 1, pp. 79-88. https://doi.org/10.1593/neo.07859
Yu, Jianjun ; Yu, Jindan ; Cordero, Kevin E. ; Johnson, Michael D. ; Ghosh, Debashis ; Rae, James M. ; Chinnaiyan, Arul M. ; Lippman, Marc E. / A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. In: Neoplasia. 2008 ; Vol. 10, No. 1. pp. 79-88.
@article{b783c9d600264eab821a6027e3c7bd3d,
title = "A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival",
abstract = "Estrogen signaling plays an essential role in breast cancer progression, and estrogen receptor (ER) status has long been a marker of hormone responsiveness. However, ER status alone has been an incomplete predictor of endocrine therapy, as some ER+ tumors, nevertheless, have poor prognosis. Here we sought to use expression profiling of ER+ breast cancer cells to screen for a robust estrogen-regulated gene signature that may serve as a better indicator of cancer outcome. We identified 532 estrogen-induced genes and further developed a 73-gene signature that best separated a training set of 286 primary breast carcinomas into prognostic subtypes by stepwise cross-validation. Notably, this signature predicts clinical outcome in over 10 patient cohorts as well as their respective ER+ subcohorts. Further, this signature separates patients who have received endocrine therapy into two prognostic subgroups, suggesting its specificity as a measure of estrogen signaling, and thus hormone sensitivity. The 73-gene signature also provides additional predictive value for patient survival, independent of other clinical parameters, and outperforms other previously reported molecular outcome signatures. Taken together, these data demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance.",
author = "Jianjun Yu and Jindan Yu and Cordero, {Kevin E.} and Johnson, {Michael D.} and Debashis Ghosh and Rae, {James M.} and Chinnaiyan, {Arul M.} and Lippman, {Marc E}",
year = "2008",
month = "1",
day = "1",
doi = "10.1593/neo.07859",
language = "English",
volume = "10",
pages = "79--88",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival

AU - Yu, Jianjun

AU - Yu, Jindan

AU - Cordero, Kevin E.

AU - Johnson, Michael D.

AU - Ghosh, Debashis

AU - Rae, James M.

AU - Chinnaiyan, Arul M.

AU - Lippman, Marc E

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Estrogen signaling plays an essential role in breast cancer progression, and estrogen receptor (ER) status has long been a marker of hormone responsiveness. However, ER status alone has been an incomplete predictor of endocrine therapy, as some ER+ tumors, nevertheless, have poor prognosis. Here we sought to use expression profiling of ER+ breast cancer cells to screen for a robust estrogen-regulated gene signature that may serve as a better indicator of cancer outcome. We identified 532 estrogen-induced genes and further developed a 73-gene signature that best separated a training set of 286 primary breast carcinomas into prognostic subtypes by stepwise cross-validation. Notably, this signature predicts clinical outcome in over 10 patient cohorts as well as their respective ER+ subcohorts. Further, this signature separates patients who have received endocrine therapy into two prognostic subgroups, suggesting its specificity as a measure of estrogen signaling, and thus hormone sensitivity. The 73-gene signature also provides additional predictive value for patient survival, independent of other clinical parameters, and outperforms other previously reported molecular outcome signatures. Taken together, these data demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance.

AB - Estrogen signaling plays an essential role in breast cancer progression, and estrogen receptor (ER) status has long been a marker of hormone responsiveness. However, ER status alone has been an incomplete predictor of endocrine therapy, as some ER+ tumors, nevertheless, have poor prognosis. Here we sought to use expression profiling of ER+ breast cancer cells to screen for a robust estrogen-regulated gene signature that may serve as a better indicator of cancer outcome. We identified 532 estrogen-induced genes and further developed a 73-gene signature that best separated a training set of 286 primary breast carcinomas into prognostic subtypes by stepwise cross-validation. Notably, this signature predicts clinical outcome in over 10 patient cohorts as well as their respective ER+ subcohorts. Further, this signature separates patients who have received endocrine therapy into two prognostic subgroups, suggesting its specificity as a measure of estrogen signaling, and thus hormone sensitivity. The 73-gene signature also provides additional predictive value for patient survival, independent of other clinical parameters, and outperforms other previously reported molecular outcome signatures. Taken together, these data demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance.

UR - http://www.scopus.com/inward/record.url?scp=38649090730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649090730&partnerID=8YFLogxK

U2 - 10.1593/neo.07859

DO - 10.1593/neo.07859

M3 - Article

VL - 10

SP - 79

EP - 88

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 1

ER -